15.95 (-%)
As of Nov 20, 2024
Source:
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Our two lead product candidates are revumenib (SNDX-5613), and axatilimab (SNDX-6352).
| Country | United States |
| Headquarters | waltham, massachusetts |
| Phone Number | 781-419-1400 |
| Industry | manufacturing |
| CEO | Michael A. Metzger |
| Website | www.syndax.com |